Given these diverse and sometimes conflicting findings as well as emerging data from our prion disease models, further investigation is needed to elucidate the mechanisms by which chronic EFV treatment modulates CYP46A1 levels and how this influences glial cell biology. This evidence concerns the gene CYP46A1 and prion disease.